サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1791763

オルガノイドとスフェロイドの世界市場

Organoids and Spheroids

出版日
ページ情報
英文 175 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.30円
オルガノイドとスフェロイドの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 175 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

オルガノイドとスフェロイドの世界市場は2030年までに36億米ドルに達すると予測

2024年に10億米ドルと推定されるオルガノイドとスフェロイドの世界市場は、分析期間2024-2030年にCAGR 23.6%で成長し、2030年には36億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるスフェロイドは、CAGR 25.3%を記録し、分析期間終了時には28億米ドルに達すると予想されます。オルガノイドセグメントの成長率は、分析期間中CAGR 18.9％と推定されます。

米国市場は2億6,610万米ドルと推定、中国はCAGR 22.3％で成長すると予測

米国のオルガノイドとスフェロイド市場は、2024年に2億6,610万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR22.3%で推移し、2030年には5億4,880万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ21.8%と20.2%と予測されています。欧州では、ドイツがCAGR約16.1%で成長すると予測されています。

世界のオルガノイドとスフェロイド市場- 主要動向と促進要因のまとめ

オルガノイドとスフェロイドはバイオメディカル調査にどのような革命をもたらしているか？

オルガノイドとスフェロイドの開発は、従来の2D細胞培養よりもヒト組織をよりよく模倣した高度な3Dモデルを提供し、生物医学研究に変革をもたらしました。幹細胞や初代組織に由来するこれらの自己組織化構造は、ヒト臓器のアーキテクチャや機能を再現しており、創薬、疾患モデリング、再生医療のための貴重なツールとなっています。従来の単層培養とは異なり、オルガノイドとスフェロイドは生体内の状態をより正確に再現するため、研究者は複雑な細胞間相互作用、腫瘍の微小環境、臓器特異的反応を研究することができます。これにより、腫瘍学、神経学、消化器病学、個別化医療において画期的な進歩がもたらされました。

技術革新はどのようにオルガノイドとスフェロイドの応用を高めているのか？

オルガノイドやスフェロイドの研究分野は、細胞培養技術、バイオプリンティング技術、マイクロ流体システムの改良により、急速な進歩を遂げています。自動化されたハイスループットスクリーニングプラットフォームは、大規模な薬物試験へのオルガノイドの採用を加速し、動物モデルへの依存を減らしています。さらに、CRISPRに基づく遺伝子編集の統合により、精密医療応用のための患者特異的オルガノイドの作製が可能になりました。新たなバイオプリンティング技術は、複雑な組織構造の作製を容易にし、再生治療の新たな可能性を開いています。バイオテクノロジー企業と学術研究機関との連携が進むことで、オルガノイドベースのモデルの商業化がさらに拡大しています。

オルガノイドとスフェロイド研究の拡大における主要課題は何か？

その可能性にもかかわらず、オルガノイドとスフェロイドを広く採用するには、標準化されたプロトコルの複雑さ、高い生産コスト、専門的知識の必要性など、いくつかのハードルがあります。また、オルガノイド培養はバッチ間で不一致を示すことがあるため、分化効率と再現性のばらつきは依然として大きな課題です。さらに、オルガノイド由来の治療法の臨床応用を規制する枠組みがないことも、商業化の障害となっています。これらの課題を克服するために、研究者たちは分化プロトコルの改良、培養液の処方の最適化、大量生産用の自動バイオリアクターの開発に取り組んでいます。

オルガノイドとスフェロイド市場の成長を後押ししているのは？

オルガノイドとスフェロイド市場の成長は、生理学的に適切な疾患モデルに対する需要の増加、精密医療への取り組みの拡大、動物実験に代わるものに対するニーズの高まりなど、いくつかの要因によってもたらされます。慢性疾患の有病率の上昇と効果的な薬剤スクリーニングツールの緊急ニーズが、製薬研究におけるオルガノイドベースのモデルの採用を加速させています。さらに、再生医療や組織工学研究に対する政府の資金援助が、オルガノイドを用いた新規治療法の開発を促進しています。臓器オンチップ・プラットフォームの出現と人工知能主導型データ解析の進歩が、市場の拡大をさらに後押ししています。

セグメント

タイプ（スフェロイド、オルガノイド）、用途（発生生物学用途、個別化医療用途、疾患病態研究用途、薬物毒性・有効性試験用途、再生医療用途）、最終用途（バイオテクノロジー・製薬最終用途、学術・調査最終用途、病院・診断センター最終用途）

調査対象企業の例

  • 3D Biomatrix Inc.
  • 3D Biotek LLC
  • AMSBIO LLC
  • Cellesce Ltd.
  • Corning Incorporated
  • Crown Bioscience Inc.
  • DefiniGEN Limited
  • Emulate Inc.
  • Greiner Bio-One International GmbH
  • Hubrecht Organoid Technology（HUB）
  • InSphero AG
  • Lonza Group AG
  • Merck KGaA
  • Mimetas B.V.
  • Organovo Holdings Inc.
  • Prellis Biologics Inc.
  • Promega Corporation
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Visikol Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32448

Global Organoids and Spheroids Market to Reach US$3.6 Billion by 2030

The global market for Organoids and Spheroids estimated at US$1.0 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 23.6% over the analysis period 2024-2030. Spheroids, one of the segments analyzed in the report, is expected to record a 25.3% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the Organoids segment is estimated at 18.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$266.1 Million While China is Forecast to Grow at 22.3% CAGR

The Organoids and Spheroids market in the U.S. is estimated at US$266.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$548.8 Million by the year 2030 trailing a CAGR of 22.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 21.8% and 20.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.1% CAGR.

Global Organoids and Spheroids Market - Key Trends & Drivers Summarized

How Are Organoids and Spheroids Revolutionizing Biomedical Research?

The development of organoids and spheroids has transformed biomedical research, offering advanced 3D models that better mimic human tissues than traditional 2D cell cultures. These self-organizing structures, derived from stem cells or primary tissues, replicate the architecture and functionality of human organs, making them invaluable tools for drug discovery, disease modeling, and regenerative medicine. Unlike conventional monolayer cultures, organoids and spheroids provide more accurate representations of in vivo conditions, allowing researchers to study complex cellular interactions, tumor microenvironments, and organ-specific responses. This has led to groundbreaking advancements in oncology, neurology, gastroenterology, and personalized medicine.

How Is Technological Innovation Enhancing the Application of Organoids and Spheroids?

The field of organoid and spheroid research has witnessed rapid advancements, driven by improvements in cell culture techniques, bioprinting technologies, and microfluidic systems. Automated high-throughput screening platforms have accelerated the adoption of organoids for large-scale drug testing, reducing the reliance on animal models. Additionally, the integration of CRISPR-based gene editing has enabled the creation of patient-specific organoids for precision medicine applications. Emerging bioprinting techniques are facilitating the fabrication of complex tissue structures, opening new possibilities for regenerative therapies. The increasing collaboration between biotechnology firms and academic research institutions is further expanding the commercialization of organoid-based models.

What Are the Key Challenges in Scaling Organoid and Spheroid Research?

Despite their potential, the widespread adoption of organoids and spheroids faces several hurdles, including the complexity of standardized protocols, high production costs, and the need for specialized expertise. The variability in differentiation efficiency and reproducibility remains a major challenge, as organoid cultures can exhibit batch-to-batch inconsistencies. Additionally, the lack of regulatory frameworks governing the clinical application of organoid-derived therapies poses an obstacle to commercialization. To overcome these challenges, researchers are working on refining differentiation protocols, optimizing culture media formulations, and developing automated bioreactors for large-scale production.

What’s Fueling the Growth of the Organoids and Spheroids Market?

The growth in the organoids and spheroids market is driven by several factors, including the increasing demand for physiologically relevant disease models, the expansion of precision medicine initiatives, and the growing need for alternatives to animal testing. The rising prevalence of chronic diseases and the urgent need for effective drug screening tools have accelerated the adoption of organoid-based models in pharmaceutical research. Additionally, government funding for regenerative medicine and tissue engineering research is fostering the development of novel organoid-based therapies. The emergence of organ-on-a-chip platforms and advancements in artificial intelligence-driven data analysis are further propelling market expansion.

SCOPE OF STUDY:

The report analyzes the Organoids and Spheroids market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Spheroids, Organoids); Application (Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application, Regenerative Medicine Application); End-Use (Biotechnology & Pharmaceutical End-Use, Academic & Research Institutes End-Use, Hospitals & Diagnostic Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • 3D Biomatrix Inc.
  • 3D Biotek LLC
  • AMSBIO LLC
  • Cellesce Ltd.
  • Corning Incorporated
  • Crown Bioscience Inc.
  • DefiniGEN Limited
  • Emulate Inc.
  • Greiner Bio-One International GmbH
  • Hubrecht Organoid Technology (HUB)
  • InSphero AG
  • Lonza Group AG
  • Merck KGaA
  • Mimetas B.V.
  • Organovo Holdings Inc.
  • Prellis Biologics Inc.
  • Promega Corporation
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Visikol Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Organoids and Spheroids - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Reliance on 3D Cell Culture Models Drives Adoption of Organoids and Spheroids
    • Shift from Animal Testing to Advanced In Vitro Models Spurs Demand Across Research Applications
    • Rapid Expansion in Oncology Drug Discovery Accelerates Use of Tumor-Derived Organoids
    • Growing Investment in Personalized Medicine Expands Adoption of Patient-Specific Organoids
    • Advancements in Stem Cell and iPSC Technologies Strengthen the Development Pipeline
    • Rising Collaborations Between Biotech and Academia Propel Growth of 3D Culture Platforms
    • Integration of Organoids in Toxicology Testing Generates New Opportunities in Safety Profiling
    • Expansion of CRISPR and Gene Editing Tools Enhances Functional Applications of Organoids
    • Emerging Use in Regenerative Medicine Throws Spotlight on Long-Term Clinical Potential
    • Demand for High-Throughput Screening Systems Drives Innovation in Miniaturized Organoid Models
    • Surge in Biopharma R&D Budgets Sustains Long-Term Growth in Organoid-Based Assays
    • Growing Ethical Concerns in Animal Research Strengthen the Case for Organoid Adoption
    • Adoption of Microfluidic and Lab-on-a-Chip Systems Expands Precision Control in 3D Cultures
    • Rising Application in Neurological and Gastrointestinal Disease Models Diversifies Market Use
    • Emergence of Organoid Biobanks Enhances Commercial and Research Value Chains
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Organoids and Spheroids Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Organoids and Spheroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Organoids and Spheroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Spheroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Spheroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals & Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Biotechnology & Pharmaceutical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Biotechnology & Pharmaceutical End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Developmental Biology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Developmental Biology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Disease Pathology Studies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Disease Pathology Studies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Drug Toxicity & Efficacy Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Drug Toxicity & Efficacy Testing Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Regenerative Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Regenerative Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • JAPAN
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • CHINA
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • EUROPE
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Organoids and Spheroids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • FRANCE
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • GERMANY
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • UNITED KINGDOM
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Organoids and Spheroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Organoids and Spheroids by Type - Spheroids and Organoids - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Organoids and Spheroids by Type - Percentage Breakdown of Value Sales for Spheroids and Organoids for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Organoids and Spheroids by End-Use - Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Organoids and Spheroids by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Centers End-Use, Biotechnology & Pharmaceutical End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Organoids and Spheroids by Application - Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Organoids and Spheroids by Application - Percentage Breakdown of Value Sales for Developmental Biology Application, Personalized Medicine Application, Disease Pathology Studies Application, Drug Toxicity & Efficacy Testing Application and Regenerative Medicine Application for the Years 2025 & 2030

IV. COMPETITION